2021
Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors
Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncology Practice 2021, 18: 258-264. PMID: 34652954, DOI: 10.1200/op.21.00240.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsFunctional statusPrimary sitePrevalence of NETsMetastatic neuroendocrine tumorsExtent of diseaseOngoing clinical trialsSomatostatin receptor statusIndividualized treatment planHeterogeneous clinical entityPace of diseaseConsideration of patientsPerformance statusSystemic therapyReceptor statusTumor characteristicsClinical entityTherapeutic optionsPathologic classificationClinical trialsTherapeutic decisionsDiagnostic modalitiesTreatment planDiseasePatients
2017
Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome.
Weickert M, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle J, Caplin M, Bergsland E, Kunz P, Anthony L, Grande E, Oberg K, Warner R, Lombard-Bohas C, Welin S, Fleming R, Kittur A, Arnold K, Yang Q, Kulke M. Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. Journal Of Clinical Oncology 2017, 35: e15692-e15692. DOI: 10.1200/jco.2017.35.15_suppl.e15692.Peer-Reviewed Original ResearchMetastatic neuroendocrine tumorsCarcinoid syndromeWeek 12Neuroendocrine tumorsTelotristat ethylWeight gainWeight lossWeight changeDouble-blind treatment periodUncontrolled carcinoid syndromeBowel movement frequencyBody mass indexCochrane-Armitage testStatistical analysis planBM frequencyAdverse eventsAnalogue therapyDiarrhea severityPerformance statusMass indexBaseline ageTreatment periodPatientsReduced survivalIncidence
2012
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investigational New Drugs 2012, 30: 2364-2370. PMID: 22331549, PMCID: PMC3703248, DOI: 10.1007/s10637-012-9800-3.Peer-Reviewed Original ResearchConceptsNeutropenic sepsisGrade 4 febrile neutropeniaDoses of ixabepiloneAdvanced solid tumorsExcellent performance statusPhase I trialSerial plasma samplesPlasma drug concentrationsRefractory advanced cancersHigh inter-individual variabilityFebrile neutropeniaPerformance statusI trialMedian ageAdvanced cancerInter-individual variabilityOral dosesSafety profileCohort 2Cohort 1Cohort 3PK variabilityOral formulationIxabepilonePatients
2010
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical And Experimental Gastroenterology 2010, Volume 3: 79-86. PMID: 21694850, PMCID: PMC3108662, DOI: 10.2147/ceg.s5928.Peer-Reviewed Original ResearchGastroenteropancreatic neuroendocrine tumorsSomatostatin analoguesNeuroendocrine tumorsTumor growthExcellent performance statusMainstay of treatmentNon-surgical therapyEnd-organ effectsExternal beam radiationNovel therapeutic trialsTyrosine kinase inhibitorsEarly promising resultsSecretion of peptidesSystemic chemotherapyLocoregional therapyPerformance statusMetastatic diseaseStandard chemotherapySurgical resectionMedical therapyTherapeutic trialsGEP-NETsTumor massMTOR inhibitorsAngiogenesis inhibitors